ALK-Abelló Dividends and Buybacks
Dividend criteria checks 0/6
ALK-Abelló does not currently pay a dividend.
Key information
0%
Dividend yield
-0.002%
Buyback Yield
| Total Shareholder Yield | -0.002% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 0% |
Recent dividend and buyback updates
Recent updates
Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity
Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Jan 23
Investors Appear Satisfied With ALK-Abelló A/S' (CPH:ALK B) Prospects
Dec 08ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets
Nov 15Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?
Oct 11ALK-Abelló A/S' (CPH:ALK B) Popularity With Investors Is Clear
Jul 23ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Jun 17Is There An Opportunity With ALK-Abelló A/S' (CPH:ALK B) 24% Undervaluation?
May 04Here's Why ALK-Abelló (CPH:ALK B) Has Caught The Eye Of Investors
Apr 16Here's Why ALK-Abelló (CPH:ALK B) Can Manage Its Debt Responsibly
Mar 12Earnings Update: ALK-Abelló A/S (CPH:ALK B) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 22
Allergy+ Strategy And Neffy Nasal Spray Will Ignite Revenue Growth And Boost Earnings
The Allergy+ strategy and neffy nasal spray deal are expected to create new revenue streams and drive growth from 2025 onward.Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ALK B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALK B's dividend payments have been increasing.
Dividend Yield vs Market
| ALK-Abelló Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ALK B) | 0% |
| Market Bottom 25% (DK) | 1.4% |
| Market Top 25% (DK) | 4.6% |
| Industry Average (Pharmaceuticals) | 2.6% |
| Analyst forecast (ALK B) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate ALK B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALK B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: ALK B is not paying a notable dividend for the Danish market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALK B has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/10 17:39 |
| End of Day Share Price | 2026/02/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ALK-Abelló A/S is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Jesper Ilsoe | Carnegie Investment Bank AB |
| Jesper Ilsøe | DNB Carnegie |